Effect of Xuebijing Combined With Ulinastatin in the Treatment of Severe Sepsis
Objective:To study the clinical efficacy of Xuebijing combined with ulinastatin in the clinical treatment of patients with severe sepsis.Methods:A retrospective study was conducted on 66 patients with severe sepsis admitted to our hospital from August 2016 to October 2022.They were divided into control group(n=33)and observation group(n=33)according to different treatment methods.The control group was treated with Xuebijing alone,and the observation group was treated with Xuebijing combined with ulinastatin.The improvement of mechanical ventilation time,ICU hospitalization time,APACHEⅡ score,tumor necrosis factor-α(TNF-α),procalcitonin concentration(PCT),plasma lipopolysaccharide(LPS)and inflammatory factors were compared between the two groups after treatment.Results:The mechanical ventilation time and ICU hospitalization time in the observation group were shorter than those in the control group(P<0.05).The APACHEⅡ score of the observation group was lower than that of the control group on the 3 rd and 7 th day after treatment(P<0.05).After treatment,LPS,TNK-α,IL-6,hs-CRP and PCT in the observation group were lower than those in the control group(P<0.05).Conclusion:In the treatment of severe sepsis,Xuebijing combined with ulinastatin has a good anti-inflammatory effect,which can improve the physiological health status of patients,shorten the mechanical ventilation time and ICU hospitalization time,and has high clinical application value.
XuebijingUlinastatinSevere sepsisClinical research
NETL
NSTL
万方数据
